We’re bringing innovation to the retina space with integrin inhibition therapy, a new class of drugs for the treatment of retinal diseases.
Risuteganib, our primary investigational compound, is leading the charge with a novel mechanism of action that works upstream to regulate all four pathways of oxidative stress that contribute to diseases such as diabetic macular edema (DME) and nonexudative age-related macular degeneration (dry AMD).
Risuteganib has successfully met the clinical endpoints in two Phase 2 trials in DME. Data from these studies suggest the ability to reduce the current burden of intravitreal injections and treat previously non-responsive patients by simultaneously targeting multiple oxidative stress pathways to restore retinal homeostasis.
As we focus on developing new treatment options for leading causes of blindness, we stay true to our company mission: helping retinal specialists better serve their patients and improving patients’ quality of life through self-sufficient, functional vision. That’s our passion. The Allegro way.